SEP 02, 2019 01:43 PM PDT

Standard Treatment Resistance Discovered in Crohn's Disease

WRITTEN BY: Nouran Amin

Researchers have mapped out more than 100,000 immune cells from biopsy samples of patients with Crohn's disease. The biopsy samples were retrieved from regions of inflamed and uninflamed Crohn's disease lesions on small intestine tissue and the analysis indicated a signature of cells implicated in the disease that does not respond to treatment. The discovery provides new clues to how we approach novel therapeutic options—findings were published in Cell.

Learn more about Crohn’s Disease:

"We designed this study in a way that defines inflammation with unprecedented precision using immunology and computational biology to get a better understanding of this disease," said co- corresponding author Judy H. Cho, MD, Senior Associate Dean for Precision Medicine, Director of The Charles Bronfman Institute for Personalized Medicine, Ward-Coleman Professor of Translational Genetics, and Professor of Medicine, and Genetics and Genomic Sciences, at the Icahn School of Medicine. "These results emphasize the limitations of current diagnostic assays and the potential for single-cell mapping tools to identify novel biomarkers for treatment response and tailored therapeutic opportunities."

After using techniques such as single-cell RNA sequencing and CyTOF technology, researchers identified for the first time a precise cell type resistant to the standard therapy for Crohn's disease, an anti-inflammatory drug called a TNF inhibitor. The drug is a major agent delivered to patients with moderate to severe Crohn's disease, however, roughly 40 percent of these patients taking the inhibitor do not respond to the therapy.

"Single-cell profiling could transform drug discovery," said co-corresponding author Miriam Merad, MD, PhD, Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai, Mount Sinai Professor in Cancer Immunology, Co-Director of the Cancer Immunology Program at The Tisch Cancer Institute and Director of the Mount Sinai Human Immune Monitoring Center. "It's really going to give us much more clarity into inflammatory bowel disease and why patients are resisting and what else we could be targeting."

Discovering a signature of cells can help identify patients who fail on this therapeutic inhibitor and avoid surgical complications. The study has allowed researchers to explore new ways of developing diagnostic methods that can determine such signature through a simple blood test. If such a diagnostic method is developed, doctors can prescribe other medicines besides a TNF inhibitor that will work well for their patients.

"Our study shows that approaches that combine high-resolution single-cell mapping of inflammatory lesions in small numbers of patients with bulk RNA sequencing on large cohorts with extensive clinical characterization leads to generalizable insights, highlighting the potential to broadly transform understanding of human multifactorial immune-mediated inflammatory diseases," said co-corresponding author Ephraim Kenigsberg, PhD, Assistant Professor of Genetics and Genomic Sciences at the Icahn Institute for Data Science and Genomic Technology.

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 15, 2019
Immunology
NOV 15, 2019
Making Opioids Safer
The opioid crisis results in 130 American deaths every day, and both prescribed and synthetic opioids are at the core of the epidemic.  Any other drug...
NOV 15, 2019
Cancer
NOV 15, 2019
Cancer drugs don't work the way we thought
New research recently published in the journal Science Translational Medicine surprises the oncological community with findings that a protein previously t...
NOV 15, 2019
Neuroscience
NOV 15, 2019
Can CRISPR Technology Treat Alzheimer's?
New drugs that seek to treat Alzheimer’s disease (AD) have a 99.6% failure rate. This makes it the only disease in the top 10 causes of death that ca...
NOV 15, 2019
Cancer
NOV 15, 2019
An alternative for immunotherapy-resistant cancer patients
A twist to traditional immunotherapies could help cancer patients’ immune systems better detect cancer cells, making this new system capable of targe...
NOV 15, 2019
Technology
NOV 15, 2019
Machine-Learning and Epigenetics Drug Discovery
Machine learning is known for detecting patterns seen in complex data—such uniqueness has proven it roles in health and medicine. Now, researchers at...
NOV 15, 2019
Genetics & Genomics
NOV 15, 2019
Can CRISPR Replace Antibiotics?
Antibiotic-resistant infections claim around 700,000 lives per year, with estimates saying that this number could swell to 10 million by 2050 (Jacobs: 2019...
Loading Comments...